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Background and Purpose ― Ischemic stroke (IS) shares many common risk factors with 
coronary artery disease (CAD). We hypothesized that genetic variants associated with 
myocardial infarction (MI) or CAD may be similarly involved in the etiology of IS. To test this 
hypothesis, we evaluated whether single nucleotide polymorphisms (SNPs) at 11 different loci 
recently associated with MI or CAD through genome-wide association studies were associated 
with IS.   
Methods ― Meta-analyses of the associations between the 11 MI-associated SNPs and IS were 
performed using 6,865 cases and 11,395 controls recruited from 9 studies.  SNPs were either 
genotyped directly or imputed; in a few cases a surrogate SNP in high linkage disequilibrium 
was chosen. Logistic regression was performed within each study to obtain study-specific betas 
and standard errors. Meta-analysis was conducted using an inverse variance weighted approach 
assuming a random effect model. 
Results ― Despite having power to detect odds ratio of 1.09-1.14 for overall IS and 1.20-1.32 for 
major stroke subtypes, none of the SNPs were significantly associated with overall IS and/or 
stroke subtypes after adjusting for multiple comparisons.  
Conclusions ― Our results suggest that the major common loci associated with MI risk do not 
have effects of similar magnitude on overall IS, but do not preclude moderate associations 
restricted to specific IS subtypes. Disparate mechanisms may be critical in the development of 
acute ischemic coronary and cerebrovascular events. 
2 
Introduction 
 Ischemic strokes (IS) comprise 87% of all strokes1.  Nearly 800,000 individuals in the US 
experience a stroke each year, making stroke one of the leading causes of serious, long-term 
disability in developed countries 1, 2.  The tendency of stroke to aggregate within families implies 
a genetic etiology, although few genetic variants have as yet been unequivocally linked to the 
common forms of IS.   
Some of the difficulty in identifying stroke susceptibility genes may arise from 
heterogeneity within the stroke phenotype, making it imperative to carry out genetic studies 
within specific subtypes of IS.  IS syndromes can, in fact, be recognized by experienced 
clinicians with a high degree of inter-rater agreement 3.  The major categories, which are based 
upon the presumed stroke mechanism, include atherosclerotic (i.e. large artery) stroke, 
cardioembolic stroke, and small vessel (lacunar) stroke.  Given disparate mechanisms, it is likely 
that different risk alleles would contribute to these different stroke subtypes.  Previous studies 
showing that a family history of stroke is more common in younger compared to older age of 
onset strokes 4-6  raise the additional possibility that the genetic contribution to stroke may differ 
by age of onset.     
IS shares many risk factors with myocardial infarction (MI) and coronary artery disease 
(CAD), including smoking and high blood pressure.  The possibility that common susceptibility 
genes might predispose to both IS and MI/CAD prompted us to examine whether genetic 
variants previously associated with MI/CAD might also be associated with IS.  To address this 
hypothesis, we evaluated whether DNA sequence variants at 11 different loci recently associated 
with MI or CAD through genome-wide association (GWA) studies were also associated with IS.  
Our analysis included 6,865 IS cases from 9 different studies, allowing us to test whether the 
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genetic variants were associated not only with overall IS, but also with the major IS subtypes and 
with age of stroke onset. 
 
Materials and Methods 
Study Populations 
This analysis includes 6,865 IS cases and 11,395 controls from 9 different studies: 
Australian Stroke Genetics Collaborative (ASGC), Bio-Repository of DNA in Stroke (BRAINS), 
Besta Cerebrovascular Diseases Registry (CEDIR), Genes Affecting Stroke Risk and Outcomes 
Study (GASROS), Genetics of Early Onset Stroke (GEOS), Graz Stroke Study (GRAZ), 
Ischemic Stroke Genetics Study and Siblings with Ischemic Stroke Study (ISGS/SWISS), Risk 
Assessment of Cerebrovascular Events (RACE) and the Vitamin Intervention for Stroke 
Prevention (VISP) study.  All stroke cases, except those from VISP study, were adjudicated for 
ischemic stroke subtype using the original TOAST system3, which assigns each case to one of 
the following categories:  cardioembolic, large artery, small vessel, other known causes and 
undetermined causes.   Controls free of stroke were selected based on study-specific criteria. For 
this report, cases and controls with a known history of MI were excluded from the analyses. 
Details of the study designs for each participating study are included in the Supplemental 
Method (http://stroke.ahajournals.org).    
All participating studies were conducted with the consent of study subjects and were 
approved by the Institutional Review Board in each institution.  
 
SNP selection  
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SNPs shown previously to be associated with MI or CAD in Caucasians were identified 
through a review of genome-wide association studies published before May 2010. MI/CAD-
associated SNPs reported in these previously published GWA studies were selected for inclusion 
in this study only if their associations with MI/CAD reached genome-wide significance (P<5x10-
8) and were replicated in at least one large independent Caucasian cohort. Based on these criteria, 
we identified 11 loci from nine chromosomes that were consistently associated with MI/CAD 
(see Table 1)7-13. 
 
Genotyping and Imputation 
The 11 MI-associated SNPs selected for inclusion in this study were genotyped by 
existing commercial genome-wide SNP platforms, KASPar SNP array (KBioscience, Herts, UK) 
and/or by Taqman assays (Applied Biosystems, Foster City, USA).  For SNPs that were not 
directly genotyped, genotypes were obtained either via imputation or the targeted SNP was 
replaced by a surrogate SNP that was in high linkage disequilibrium (LD r2 > 0.8) with the target 
SNP. A detailed description on the genotyping and imputation methods for each participating site 
is provided in Supplemental Table S1.     
 
Statistical Analysis 
 Site-specific logistic regression analysis was performed to test for associations of each 
individual SNP with IS under an additive model, and then site-specific beta coefficients (β) and 
standard errors (S.E.) were pooled in meta-analyses.  A genotype risk score was also computed 
for each individual by summing the number of MI/CAD-risk alleles across each of the 11 loci 
(score 1).  Each SNP was given equal weights rather than weights based on their effect sizes (β) 
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for MI/CAD in the risk score calculation given that we do not know the effects of these SNPs on 
stroke and the assumption that they would have similar effects on stroke as they do on MI seems 
unjustified. Additionally, we computed a genotype risk score that summed the number of 
MI/CAD-risk alleles across 10 loci, excluding SNP rs4977574 on chromosome 9, because SNPs 
near this locus have previously been reported to be associated with large artery stroke (score 2)14.  
Each genotype risk score was used as a continuous independent variable in the logistic regression 
model to obtain the joint additive effects of all MI/CAD-associated SNPs on the risk of IS. The β 
of the genotype risk score represents the increase in log odds of stroke associated with having 
one additional MI/CAD-risk allele. The GRAZ study was not included in the score analyses 
because three of the 11 SNPs were not genotyped directly and could not be imputed with 
acceptable quality scores (rs6725887, rs9818870 and rs9982601). Overall, about 35% of the 
individuals in whom one or more SNPs were not genotyped or imputed were removed from the 
genotype risk score analysis.  For ease of result interpretation, all odds ratios were designated 
with the previously published non-risk allele as the reference so that the odds ratio reflects the 
effect of the MI-associated risk allele.  Association analyses were adjusted for study-specific 
covariates (e.g. age, sex and population structure) (see Supplemental Table S2). 
Meta-analysis was performed using a variance-weighted approach assuming a random 
effect model (DerSimonian & Laird method)15, which takes heterogeneity of the genetic effects 
across studies into account.  Between-study heterogeneity was estimated using Cochran’s Q 
statistic, which is the summation of the squared weighted difference between the study-specific 
effect and the overall effect size (estimated by the fixed effect), as well as I2 statistics, which 
represent the percent of total variation across studies due to heterogeneity after accounting for 
variability due to chance. All meta-analyses were performed using the metan module 
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implemented in STATA 10 (StataCorp, College Station, TX).  Analyses were carried out for 
total IS, by stroke subtype and by age of stroke onset (≤ 50 yrs, 50-70 yrs, and ≥ 70 yrs). 
With our total sample size (6,865 cases), we had 80% power to detect odds ratios of 1.09 
~ 1.14 for overall IS and odds ratios of 1.20-1.32 for major stroke subtypes (~1,000 cases) for 
variants with allele frequency 10-50% (Bonferroni-corrected α = 0.0045 =0.05/11 SNPs). In this 
report, nominal p-values were provided for all the analyses. 
 
Results 
Study population characteristics 
This study included 6,865 cases and 11,395 controls recruited from 9 studies across 
North America, Europe, Australia and South Asia.  Stroke cases ranged in age between 15 to 101 
years.  Among cases with subtype information available, the three major stroke subtypes, 
cardioembolic, large artery (atherosclerotic) and small vessel (lacunar), accounted for ~ 20.9% (n 
= 1,216), 19.6% (n = 1,137) and 18.0% (n = 1,043) of the cases, respectively; the remaining 
cases were attributed to either “other known causes” (5.6%; n = 324) or “undetermined causes” 
(35.9%; n = 2,084). The majority of the study participants were of European ancestry with the 
exception of those enrolled in the RACE study (1890 cases and 4625 controls), which has 
enrolled participants of South Asian origin.  Detailed characteristics of the participating studies 
are provided in Supplemental Table S3.  
 
Associations of MI/CAD SNPs and overall IS risk  
In the total sample, the meta-analysis odds ratios for all 11 SNPs ranged from 0.92 to 
1.11 (Table 2). Only two SNPs were nominally associated with IS: rs11206510 at PCSK9 (OR of 
7 
0.92; 95% CI: 0.86-0.99; P=0.03; allele T) and rs3184504 at SH2B3 (OR of 1.11; 95% CI: 1.01-
1.21; P=0.03; allele T). This association would not have withstood a conservative Bonferroni 
correction (α = 0.05/11, or 0.0045).  Although there was no significant evidence for 
heterogeneity of effect size across studies for rs11206510, the direction of effect was not 
consistent across studies with ORs ranging from 0.80 (RACE study) to 1.12 (CEDIR study) 
(Cochran’s Q statistic = 8.1, P =0.4) (Figure S1). rs3184504, on the other hand, showed 
significance evidence for heterogeneity (Cochran’s Q statistic = 20.9, P =0.01) with one study 
(BRAINS) showing opposite effect as compared with other studies.  We also examined the joint 
effect of these MI/CAD-associated SNPs by testing for association with the genotype scores and 
found no significant effect for either genotype score 1 or score 2 (OR = 1.02, P = 0.2 for both 
scores).  Removing the RACE study, the only study that had participants of South Asian origin, 
did not change results significantly although the association with rs11206510 and rs3184504 
became less significant (OR=0.94, P=0.10 and 1.10, P=0.06, respectively) (Supplementary Table 
S4). 
We further stratified the associations between MI/CAD-associated SNPs and overall IS 
according to age of stroke onset: early (≤ 50 yrs), intermediate (50 yrs < age < 70 yrs) and late 
onset (age ≥ 70 yrs). None of the associations were statistically significant in the age-stratified 
analyses, either (Supplemental Table S5).  
 
Associations with major ischemic stroke subtypes 
 We next examined the effects of MI/CAD-associated SNPs on TOAST-defined subtypes 
(Table 3). Nominally significant associations (0.03 < p < 0.05) were observed for four of the 
different TOAST subtypes.  The MI/CAD-associated risk allele at rs9818870 in MRAS was 
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associated with the cardioembolic stroke subtype (OR= 1.17, 95% C.I.: 1.02-1.35; P=0.03); the 
MI-associated risk allele at rs17465637 in MIA3 was associated with the small vessel stroke 
subtype (OR=1.12, 95% C.I.: 1.00-1.26; P=0.05); and the MI-associated risk allele at rs3184504 
in SH2B3 was associated with strokes due to other known causes (OR=1.33, 95% C.I.: 1.02-
1.72; P=0.04). In addition, rs11206510 was associated with strokes due to other undetermined 
causes, although the allele conferring protection against MI was associated with stroke risk (OR 
= 0.86, 95% C.I.: 0.76-0.99; P =0.03).  The ASGC study had a much higher OR and a wide 
confidence interval for rs11206510 association, but this study contributed only 11 cases of 
undetermined causes in the analysis.  Excluding the ASGC study from the meta-analysis resulted 
in an OR of 0.86 (95% CI: 0.76-0.97, P=0.01) for the association between rs11206510 and 
undetermined causes of stroke.  The ANRIL rs4977574 SNP was very modestly (and not 
significantly) associated with the large artery stroke subtype (OR=1.09, 95% C.I.: 0.99-1.20; 
P=0.09), nor was it associated with any other stroke subtype.  None of these results withstand 
correction for multiple testing.  Forest plots showing the most strongly associated SNP with each 
subtype are in Figure S2.  
 
Discussion 
It is of interest to consider whether common loci influence susceptibility to MI/CAD and 
stroke to the extent that such loci could elucidate common genetic and/or biologic pathways.  
Given that the 11SNPs tested in this study were associated with MI/CAD in previous GWA 
studies, they likely are among the common SNPs having the largest effect sizes.  The risk alleles 
at these loci were associated with increases of 12-20% in MI risk, with the exception of 
rs4977574 in ANRIL, for which the risk allele was associated with a 28% increase in Europeans 
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7, 8, 13. In contrast, none of the MI/CAD risk alleles at these loci were significantly associated 
with risk of overall IS, with the estimated odds ratios ranging from 0.92 to 1.11 (i.e., 8% 
reduction to 11% increase in odds of stroke per allele).   
It is possible that failure to detect associations of these SNPs with the combined IS 
endpoint might be partially attributable to the heterogeneity of the IS phenotype.  The large size 
of our sample provided us with the opportunity to evaluate the association of these SNPs to 
subtypes of ischemic stroke.  Similar to the combined IS endpoint, we did not find any 
significant associations of MI/CAD SNPs (or the joint genotyping risk scores) with any of the 
stroke subtypes.  Given that this study included more than 6,800 total cases and more than 1,000 
cases for the major stroke subtypes, we have sufficient power to detect even small effects on 
overall stroke although more modest power to detect associations with stroke subtype.  
Therefore, our findings suggest that these MI/CAD-associated SNPs do not have effects of 
similar magnitude on overall stroke as they do on MI/CAD.  If an association does exist, it is 
likely to be very modest for overall IS or restricted to a single stroke subtype. 
Although the SNP associations with stroke subtypes did not reach statistical significance, 
it is interesting that the strongest associations we observed in the subtype analysis were genes 
involved in cell regulation or signaling. For example, the strongest association with 
cardioembolic stroke was the MI-risk allele at rs9818870 in MRAS (OR= 1.17, P=0.03).  MRAS, 
an intracellular signal transducer, is highly expressed in the cardiovascular system, and may be 
involved in cell adhesion 7, 8, 16.  The strongest association with small vessel stroke was the MI-
risk allele at rs17465637 in MIA3 (OR=1.12, P=0.05), which encodes melanoma inhibitory 
activity 3 and is associated with cell adhesion and migration in inflammatory pathways17 .  It 
should also be noted that rs4977574 near ANRIL was very modestly associated with the large 
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artery subtype (OR=1.09, P=0.09).  Although the association did not achieve statistical 
significance in our study, other SNPs in the ANRIL region on chromosome 9p21 have previously 
been associated with large artery stroke, with the strongest signal found with SNP rs1537378 
(OR=1.21, 95% CI: 1.09-1.35, P=0.0005)14. Interestingly, rs1537378 is not in high LD with our 
target SNP rs4977574 (r2=0.5), suggesting these 2 SNPs may represent different association 
signals or each of them may be tagging the causal variant imperfectly (assuming the association 
is indeed true). ANRIL encodes an antisense noncoding RNA that may disrupt other genes in the 
region, including CDKN2A and CDKN2B, two genes that play a key role in regulating cell 
proliferation, senescence, and apoptosis.  We also observed the MI-associated risk allele at 
rs3184504 in SH2B3 to be nominally significantly associated with strokes due to other known 
causes (OR=1.33, 95% C.I.: 1.02-1.72; P=0.04).  It has been hypothesized that this SNP could 
reduce the anti-inflammatory activity of SH2B3, which is expressed in the vasculature, thereby 
leading to the development of plaque development and/or progression in coronary arteries13.   
In contrast, SNPs whose effects on MI are likely to be mediated though lipid metabolism, 
e.g., rs1122608 at SMARCA4/LDLR (19p13), rs646776 at the CELSR2/PSRC1/SORT1 locus 
(1p13) and rs11206510 at PCSK9 (1p32), have minimal effects on IS or any of its subtypes, and 
in some cases, even showed opposite effects on stroke.  For example, the MI/CAD-associated 
risk allele of rs11206510 at PCSK9, a gene involved in cholesterol homeostasis, was modestly 
associated with decreased risk of overall stroke (OR=0.92, P=0.03) or strokes due to 
undetermined causes (OR=0.86, P=0.03). Our analyses suggest that genes involved in lipid 
metabolism do not predispose individuals to increased stroke risk as they do for MI although 
replications will be needed to confirm these associations. 
11 
 Taken together, our results suggest that the major common loci associated with MI/CAD 
risk do not have large effects on stroke. However, although our analyses did not reveal any 
significant associations between MI/CAD SNPs and stroke, the chromosomal regions harboring 
these loci might still contain stroke-related SNPs that are not in high LD with the MI-associated 
SNPs, as the example of chromosome 9p region14.  A limitation of our meta-analysis is that all 
included studies are case-control-based and some have included recurrent stroke, thus allowing 
for the possibility of selection toward milder strokes (due to survival bias). It is possible that 
these genetic MI/CAD variants could be associated with more severe forms of stroke, but 
longitudinal studies that follow healthy cohorts for stroke occurrence prospectively would be 
needed to address this issue. Finally, our analyses were based on 11 SNPs unequivocally 
associated with MI and/or CAD identified from the first wave of meta-analyses for these traits.  
A second wave of even larger meta-analyses of these traits is in progress that will likely generate 
additional associations.  We can expect most of these newly associated SNPs to have even 
smaller effect sizes on MI and CAD.  In fact, in September 2011, 17 additional CAD-associated 
SNPs were identified by even larger meta-analyses, and the reported effect sizes for these newly 
identified SNPs, as expected, were smaller (ranging from 1.06-1.17) than the original 11 SNPs 
used in the present analysis18-21. But this does not necessarily mean that these SNPs will have 
smaller effect sizes on stroke.  Indeed, it is very possible that such SNPs may be in gene 
pathways that are more relevant to stroke than are the pathways associated with the currently 
known MI SNPs.  Thus, it will be important to monitor new SNPs identified, even those with 
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of risk allele 
Region Position Reported gene Previous 
reported odds 
ratio on MI 
Reference 
rs11206510 C/T 0.81 1p32 55,268,627 PCSK9 1.15 8 
rs646776 C/T 0.81 1p13 109,620,053 CELSR2-PSRC1-SORT1 1.17 8, 10 
rs17465637 A/C 0.72 1q41 220,890,152 MIA3 1.13 8, 12 
rs6725887 T/C 0.14 2q33 203,454,130 WDR12 1.17 8 
rs9818870 C/T 0.16 3q22.2 139,604,812 MRAS 1.15 7 
rs12526453 G/C 0.65 6p24 13,035,530 PHACTR1 1.12 8 
rs4977574 A/G 0.56 9p21 22,088,574 ANRIL/CDKN2B-AS1 1.28 8, 9, 11 
rs1746048 T/C 0.84 10q11 44,095,830 CXCL12 1.14 8, 12 
rs3184504 C/T 0.39 12q24 110,368,991 SH2B3 1.13 13 
rs1122608 T/G 0.75 19p13 11,024,601 SMARCA4-LDLR 1.15 8 




* Risk allele is the allele associated with increased risk of MI or CAD
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Table 2. Association results of the 11 MI/CAD-risk loci and risk scores with ischemic stroke 




Q (P-value) I2, %  OR (95% CI)
 * P 
Minimal OR detectable in 
current study† 
rs11206510 T 8.12 (0.42) 1.53  0.92 (0.86, 0.99) 0.03 1.13 
rs646776 T 9.02 (0.34) 11.34  0.95 (0.89, 1.01) 0.12 1.13 
rs17465637 C 3.09 (0.93) 0  1.03 (0.97, 1.09) 0.37 1.11 
rs6725887 C 13.38 (0.06) 47.67  1.03 (0.90, 1.16) 0.69 1.13 
rs9818870 T 5.45 (0.61) 0  1.03 (0.95, 1.11) 0.47 1.12 
rs12526453 C 8.81 (0.36) 9.2  1.00 (0.95, 1.06) 0.92 1.10 
rs4977574 G 4.17 (0.84) 0  1.02 (0.97, 1.07) 0.54 1.09 
rs1746048 C 5.37 (0.72) 0  1.03 (0.96, 1.10) 0.38 1.14 
rs3184504 T 20.87 (0.01) 61.67  1.11 (1.01, 1.21) 0.03 1.09 
rs1122608 G 6.31 (0.61) 0  1.00 (0.95, 1.06) 0.92 1.11 
rs9982601 T 6.20 (0.52) 0  1.00 (0.93, 1.09) 0.95 1.13 
score1 n/a 12.31 (0.09) 43.15  1.02 (0.99, 1.05) 0.23 n/a 
22 
score2 n/a 14.44 (0.04) 51.52  1.02 (0.99, 1.06) 0.23 n/a 
OR: odds ratio; CI: confidence interval; n/a: not applicable; P: p-value 
* OR: odds ratios reflects the effect of the MI-associated risk allele with the previously published MI non-risk allele as the reference 
allele defined in Table 1.  
† The minimal odds ratios that current sample size (6,865 overall IS cases) can detect with at least 80% power (α=0.0045).
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Table 3. Association results of the 11 MI/CAD-risk loci and risk scores with ischemic stroke, by TOAST subtypes 
 Cardioembolic 
(n=1,216) 
 Large Artery 
(n=1,137) 
 Small Vessel 
(n=1,043) 









P  OR  
(95% CI)* 
P  OR  
(95% CI)* 
P  OR  
(95% CI)* 




(0.89, 1.18) 0.78 
 0.91 
(0.80, 1.04) 0.17 
 1.05 
(0.91, 1.21) 0.50 
 0.89  
(0.72, 1.11) 0.32 
 0.86  
(0.76, 0.99) 0.03 
rs646776 0.93 
(0.83, 1.05) 0.25 
 0.91 
(0.81, 1.03) 0.12 
 0.95 
(0.84, 1.07) 0.38 
 1.01  
(0.78, 1.31) 0.94 
 0.93  
(0.82, 1.05) 0.24 
rs17465637 1.01 
(0.89, 1.16) 0.86 
 0.98 
(0.87, 1.09) 0.69 
 1.12 
(1.00, 1.26) 0.05 
 0.96  
(0.79, 1.17) 0.69 
 1.01  
(0.92, 1.10) 0.90 
rs6725887 0.98 
(0.83, 1.16) 0.84 
 1.01 
(0.85, 1.19) 0.93 
 0.91 
(0.76, 1.09) 0.30 
 1.45  
(0.93, 2.26) 0.10 
 0.96  
(0.83, 1.11) 0.58 
rs9818870 1.17 
(1.02, 1.35) 0.03 
 0.97 
(0.83, 1.13) 0.66 
 0.91 
(0.77, 1.07) 0.24 
 1.32  
(0.92, 1.89) 0.13 
 0.99  
(0.87, 1.12) 0.90 
24 
rs12526453 1.06 
(0.95, 1.18) 0.31 
 0.93 
(0.83, 1.03) 0.15 
 0.90 
(0.80, 1.02) 0.09 
 1.03  
(0.85, 1.25) 0.74 
 1.00  
(0.91, 1.09) 0.99 
rs4977574 1.02 
(0.89, 1.17) 0.82 
 1.09 
(0.99, 1.20) 0.09 
 1.03 
(0.94, 1.14) 0.52 
 0.91  
(0.69, 1.18) 0.47 
 1.01  
(0.94, 1.09) 0.72 
rs1746048 0.99 
(0.88, 1.12) 0.93 
 1.05 
(0.92, 1.2) 0.44 
 1.01 
(0.86, 1.18) 0.94 
 0.97  
(0.70, 1.33) 0.85 
 1.00  
(0.91, 1.1) 0.96 
rs3184504 1.05 
(0.91, 1.22) 0.51 
 1.16 
(0.96, 1.39) 0.11 
 1.03 
(0.89, 1.20) 0.68 
 1.33  
(1.02, 1.72) 0.04 
 1.12  
(0.98, 1.27) 0.11 
rs1122608 0.98 
(0.88, 1.09) 0.67 
 1.06 
(0.95, 1.18) 0.33 
 1.03 
(0.92, 1.15) 0.66 
 1.03  
(0.85, 1.26) 0.75 
 0.99  
(0.91, 1.07) 0.74 
rs9982601 1.05 
(0.89, 1.25) 0.55 
 1.04 
(0.89, 1.22) 0.63 
 1.06 
(0.88, 1.27) 0.55 
 1.15  
(0.83, 1.60) 0.39 
 1.02  
(0.85, 1.22) 0.85 
score1 1.02 
(0.98, 1.07) 0.29 
 1.02 
(0.97, 1.06) 0.47 
 1.01 
(0.95, 1.07) 0.85 
 1.06  
(0.98, 1.14) 0.16 
 1.00  
(0.96, 1.04) 0.97 
score2 1.04 
(0.99, 1.08) 0.11 
 1.01 
(0.96, 1.08) 0.63 
 1.00 
(0.94, 1.07) 0.91 
 1.08  
(1.01, 1.17) 0.03 
 1.00  
(0.96, 1.05) 0.92 
n: number of cases; OR: odds ratio; P: p-value 
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* OR: odds ratio reflects the effect of the MI-associated risk allele with the previously published MI non-risk allele as the reference 
allele defined in Table 1.  
 
